Top Markets
Coin of the day
9 Meters Biopharma, Inc. 9 Meters Biopharma, Inc.

9 Meters Biopharma, Inc.

NMTR
株式のランク #40890
Based in Raleigh, North Carolina, 9 Meters Biopharma, Inc. operates as a... Based in Raleigh, North Carolina, 9 Meters Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. Its core mission is to innovate treatments for individuals suffering from rare digestive conditions, gastrointestinal disorders with inadequate therapeutic options, and other severe debilitating ailments. The company's pipeline features several promising drug candidates. Larazotide, an 8-amino acid peptide, is currently in a Phase 3 clinical trial for the treatment of celiac disease and is also being assessed in a Phase IIa study for multi-system inflammatory syndrome. Another key asset, Vurolenatide, a long-acting injectable glucagon-like peptide-1, is undergoing Phase 2 clinical trials to address short bowel syndrome. Additionally, 9 Meters Biopharma is advancing other compounds, including NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist intended for the prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody designed to target specific obesity disorders; and NM-004, a double-cleaved mesalamine combined with an immunomodulator, slated for rare and/or orphan indications.
株価
$0.0169
最終同期: 2023-08-21
時価総額
$66.40K
変化(1日)
4.32%
変化(1年)
0.00%
US
取引 9 Meters Biopharma, Inc. (NMTR)

カテゴリー

9 Meters Biopharma, Inc.(NMTR)の配当利回りの履歴
9 Meters Biopharma, Inc.(銘柄コード: NMTR)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
9 Meters Biopharma, Inc.(NMTR)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)